Romano Brothers & Co’s AstraZeneca AZN Stock Holding History

Romano Brothers & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-437	Closed	-$59.2K	–	353
2022 Q4	$59.2K	Buy	+437	New	+$54.8K	0.01%	441

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Romano Brothers & Co's AZN Position: Q1 2023 in Review

Romano Brothers & Co sold out of AstraZeneca (AZN) in Q1 2023, closing a stake of 437 shares — an estimated $59.2K sold.

Romano Brothers & Co first reported a position in AZN in Q4 2022 and held it in 1 quarter. The position peaked at $59.2K in Q4 2022. 1,054 funds tracked by Wall St. Rank hold AZN as of Q1 2023.

Romano Brothers & Co reported no remaining AstraZeneca position as of Q1 2023 after selling out during the quarter.
Romano Brothers & Co sold 437 AstraZeneca shares in Q1 2023, an estimated $59.2K.
Romano Brothers & Co first reported a position in AstraZeneca in Q4 2022 and held it in 1 quarter.
Romano Brothers & Co's AstraZeneca position peaked at $59.2K in Q4 2022.
1,054 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.